Our work has two main streams. First, we have a long-standing interest in deciphering the molecular basis of genome maintenance with a particular focus on DNA repair. This has applications in oncology, immunology and ageing research. Second, we aim to develop new approaches to combat disease. In the past, we have used CRISPR/Cas9 screens to map synthetic lethality networks relevant to cancer and we are also now interested in harnessing the power of induced proximity to building new therapies.
- 2021 Finalist, Bloom Burton Prize
- 2015 Paul Marks Prize for Cancer Research
- 2015 Fellow of the Royal Society of Canada
- 2010 Young Investigator Prize, Canadian Cancer Society
- 2009 Caldwell Partners Canada’s Top 40 under 40
- Lunenfeld-Tanenbaum Research Institute
- Co-founder of Repare Therapeutics